HCG (Human Chorionic Gonadotropin): Reference Research Data

What Is HCG?

Human chorionic gonadotropin (HCG) is a heterodimeric glycoprotein hormone produced by the syncytiotrophoblast of the placenta during pregnancy. Structurally it consists of a 92-amino-acid alpha subunit — shared identically with luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH) — non-covalently associated with a 145-amino-acid beta subunit that carries the hormone-specific information.^[4] The mature heterodimer is roughly 36-40 kDa depending on glycosylation, with up to eight N- and O-linked carbohydrate side chains. Those chains are not decorative: they extend circulating half-life relative to LH and they modulate receptor signalling bias.

The beta-HCG subunit shares approximately 80% sequence homology with the LH beta subunit, with a unique C-terminal peptide extension of 24 amino acids carrying additional O-linked glycans. That homology is the reason HCG and LH both engage the same receptor on the gonadal cell surface — and the reason a beta-HCG immunoassay is the diagnostic backbone of pregnancy testing in clinical chemistry. For research-reference purposes, the practical consequence is that HCG behaves as a long-acting LH agonist with greater receptor occupancy than endogenous LH at equivalent molar concentrations.

Unlike short peptides such as KPV or growth-hormone-axis molecules like the CJC-1295 + Ipamorelin blend, HCG is not gravimetrically quantified for research handling. It is measured in international units (IU) calibrated against the WHO 5th International Standard for Chorionic Gonadotropin (NIBSC 07/364), because biological potency depends on glycosylation and the presence or absence of nicked subunits, not simply on peptide mass.^[5]

Mechanism: LH/CG Receptor Activation & Downstream Steroidogenesis

HCG and LH share a single receptor — the LH/choriogonadotropin receptor (LHCGR) — a class A G-protein-coupled receptor with a large extracellular leucine-rich repeat domain that binds the heterodimeric hormone with sub-nanomolar affinity. The receptor is expressed primarily on Leydig cells in the male testis and on theca and granulosa cells in the female ovary, with smaller populations described in the uterus, placenta, and fetal tissues.^[4]

The canonical signalling cascade is well characterised:

• Gs-coupled cAMP/PKA activation. HCG binding triggers receptor coupling to Gαs, adenylyl cyclase activation, and a rise in intracellular cAMP. PKA then phosphorylates downstream targets including the steroidogenic acute regulatory protein (StAR), which controls cholesterol transport into the inner mitochondrial membrane — the rate-limiting step of steroid hormone synthesis.
• Leydig-cell testosterone induction. In males, cAMP-driven StAR activation increases conversion of cholesterol to pregnenolone via the CYP11A1 (P450scc) enzyme, with downstream flux through 17α-hydroxylase, 17,20-lyase, 3β-HSD, and 17β-HSD to testosterone. HCG stimulation produces a measurable serum testosterone rise within hours in research-reference protocols.
• Ovarian steroidogenesis and ovulation triggering. In females, HCG drives theca-cell androgen production (substrate for granulosa-cell aromatization to estradiol) and, at the LH-surge-equivalent dose used in assisted reproduction, triggers final oocyte maturation and follicular rupture.
• Secondary Gq/PLC signalling at higher concentrations. The LH/CG receptor also couples to Gq at higher ligand occupancy, producing inositol triphosphate and diacylglycerol second messengers and contributing to receptor desensitization kinetics that differ from LH because of HCG's longer half-life and greater receptor occupancy time.

A practical research-reference point: HCG's pharmacokinetic profile — circulating half-life of roughly 24-36 hours after intramuscular administration of urinary-derived product, compared to LH's roughly 20-minute half-life — is the reason single-dose HCG protocols are used to mimic an LH surge in fertility research, and why repeat-dose protocols produce sustained Leydig-cell stimulation rather than the pulsatile pattern that endogenous LH provides.

Recombinant vs Urinary-Derived HCG: Pregnyl, Novarel, Ovidrel

Three product lines dominate the global HCG supply, and the differences matter for research-reference comparability.

The biological case for recombinant choriogonadotropin alfa (Ovidrel) is straightforward: a defined CHO-cell expression system produces a more homogeneous glycoform population than urine-extracted material, with batch-to-batch variability constrained by manufacturing controls rather than donor urine composition. The trade-off is that the 250 mcg pre-filled syringe is a fixed, non-divisible unit, which constrains protocol flexibility relative to a reconstitutable lyophilized vial.

For research-reference comparability, the urinary-derived products carry a heterogeneous glycoform mix that includes nicked and hyperglycosylated species; this heterogeneity is exactly what the IU-based potency standard exists to control. Equating "5,000 IU urinary HCG" with "5,000 IU recombinant HCG" on the basis of label alone, without bioassay-anchored equivalence, is the classic error in cross-product research design.

Fertility Research Applications & the APHRODITE Criteria

HCG's most extensively studied research application is male infertility, specifically the management of secondary hypogonadism and the stratification of men with non-obstructive azoospermia (NOA) who may benefit from gonadotropin-based fertility therapy. In 2024, Esteves and colleagues published the APHRODITE criteria — Addressing male Patients with Hypogonadism and/or infeRtility Owing to altereD, Idiopathic TEsticular function — in Reproductive BioMedicine Online, as a consensus classification of infertile men for trials of hormonal treatment.^[6] A 2025 Andrology review by Esteves, Viana, Achermann and Santi applies the criteria to HCG-based treatment of non-obstructive azoospermia.^[1]

The criteria define five groups from clinical findings, semen analysis and hormone tests: (1) hypogonadotropic hypogonadism, acquired or congenital; (2) idiopathic infertility with reduced semen parameters and normal FSH and total testosterone; (3) a hypogonadal state with reduced semen parameters, normal FSH and reduced total testosterone; (4) reduced semen parameters with elevated FSH and reduced or normal total testosterone; and (5) unexplained male infertility within unexplained couple infertility.^[6] Hypogonadotropic hypogonadism (group 1) is the setting in which gonadotropin treatment, including HCG, has the most established evidence; its use in other forms of non-obstructive azoospermia is still debated.^[1]

The authors propose APHRODITE as a common basis for future trials, so that results are reported within defined patient groups rather than across mixed cohorts.^[1] A protocol for a multicentre randomised controlled trial of gonadotropin therapy in idiopathic hypogonadal non-obstructive azoospermia (APHRODITE groups 3–4) was published in Frontiers in Reproductive Health in July 2026; it describes the trial design and does not report outcomes.^[7]

Adjacent endocrine-axis research-reference material on this site covers tesamorelin (GHRH analog) and the CJC-1295 + Ipamorelin GH-secretagogue blend as separate hypothalamic-pituitary axes; HCG sits on the hypothalamic-pituitary-gonadal axis and is not interchangeable with growth-hormone-axis tools.

Post-Androgen Spermatogenesis Recovery — Smit et al. 2025

A second 2020s-era data stream centres on men presenting with azoospermia or severe oligozoospermia following non-prescribed androgen use. Exogenous androgen suppresses hypothalamic GnRH, collapsing pituitary LH and FSH output and, secondarily, intratesticular testosterone and spermatogenesis. Recovery after discontinuation is variable and often incomplete, and HCG-based treatment is one of the studied interventions.

Smit, Verdegaal, and Bond reported a retrospective analysis in F&S Reports (2025) of 19 men at a Dutch harm-reduction clinic who were unwilling to stop non-prescribed androgens and were given HCG. Total sperm count improved in 16 of 19 men and total motile sperm count in 17 of 19, and the share with a normal motile count rose from 5% to 58%. Some men stayed oligozoospermic or azoospermic, and none of the factors tested (age, duration of prior androgen use, time between analyses, or HCG amount) significantly predicted the change.^[2]

Two interpretive cautions apply for a research-reference reader. First, a small retrospective clinic cohort without a control group cannot be generalised to all men who use androgens. Second, the published data describe outcomes inside a regulated clinical setting; nothing in the published paper supports a self-administered "post-cycle" framing, and Remy Research does not provide such framing on any catalog or research page.

The honest summary across the published record is consistent: HCG has reproducible mechanistic and clinical evidence in fertility research, with the strongest signal in well-stratified secondary-hypogonadism and post-androgen-suppression populations. It is not framed here for human use.

U.S. Supply Status & the BPCIA Reclassification

The main regulatory event in modern U.S. HCG supply is the March 23, 2020 transition under the Biologics Price Competition and Innovation Act (BPCIA). HCG is a protein hormone and was never a small molecule, but it had been approved through new drug applications. On that date, approved HCG products were deemed to hold biologics licences, as part of a broader FDA "deemed to be a license" transition that also covered insulin, FSH and other protein products.^[3]

Two effects followed:

• End of routine pharmacy compounding. As a licensed biologic, HCG could no longer be routinely compounded by pharmacies. In a 2023 survey, six of the eight pharmacies that had stopped making HCG or FSH cited the 2020 change.^[3]
• Reliance on approved products. U.S. patients now depend on approved HCG products such as Pregnyl, Novarel and Ovidrel. Their availability varies over time; we found no current FDA drug-shortage listing for HCG as of October 7, 2026.

For research-reference purposes, the U.S. regulatory situation is informational rather than directly governing. Remy Research does not publish a fixed restock timeline for the HCG 5000 IU research-reference vial. In sport, chorionic gonadotrophin is prohibited in males at all times under section S2.2.1 of the WADA 2027 Prohibited List (published 21 September 2026, in force 1 January 2027). For a comparison with other gonadal-axis peptides, see HCG vs gonadorelin vs kisspeptin.

Reconstitution & Storage Protocol

HCG handling follows the standard lyophilized-glycoprotein research-reference protocol, with one critical convention that separates it from most other peptides in this library.

1. IU measurement, not mg

All reconstitution math for HCG should be done in international units, not milligrams. The label on a 5,000 IU vial is the bioassay-anchored unit; converting to a milligram or microgram equivalent for protocol design is the wrong abstraction and reliably produces cross-product mismatches. A short discussion of unit conversion sits in the reconstitution calculator for the molecules that do use mg labelling; HCG is intentionally not represented there in mg form for this reason.

2. Bacteriostatic water reconstitution

Lyophilized HCG is typically reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water) for research-reference purposes. The volume of diluent determines the resulting IU/mL concentration: 1 mL of bacteriostatic water added to a 5,000 IU vial yields 5,000 IU/mL; 5 mL yields 1,000 IU/mL. Vial mixing should be by gentle swirling, never vortexing, to avoid mechanical denaturation of the glycoprotein.

3. Cold-chain after reconstitution

Reconstituted HCG is unstable at room temperature and should be stored at 2-8°C with use within roughly 30-60 days of reconstitution depending on diluent and vial integrity. Lyophilized HCG, by contrast, is significantly more stable: published manufacturer data support multi-year stability for properly sealed lyophilized vials under refrigeration. The catalog vial ships with cold-chain handling per the practice documented across the COA library.

4. Glycoprotein-specific handling

Repeated freeze-thaw cycles degrade glycoprotein activity disproportionately to peptide bond cleavage — alpha/beta subunit dissociation is the dominant failure mode, and a reconstituted HCG solution that has been frozen and thawed once should be treated as having reduced potency even if no visible precipitation has occurred. Single-use aliquoting at reconstitution is the standard research-reference practice for this reason.

HCG Research-Use Supply & Format — Currently Out of Stock

Remy Research lists the HCG 5000 IU research-reference vial as an IU-keyed lyophilized chorionic gonadotropin format with cold-chain handling, supplied strictly for in-vitro research use only. The line is currently out of stock.

No restock date is published, deliberately. Upstream chorionic gonadotropin supply varies, and a fixed restock timeline cannot be honestly committed. The product page exposes a restock-alert flow that captures researcher email addresses and notifies the list when the line returns; see the product page for current pricing and availability. The page is maintained as a research-reference listing during the OOS window rather than removed.

Adjacent endocrine-axis research-reference compounds that are typically in catalog include the CJC-1295 + Ipamorelin GH-secretagogue blend and the tesamorelin GHRH analog; both sit on the hypothalamic-pituitary axis but are not substitutes for HCG, which is the only listed compound on the hypothalamic-pituitary-gonadal axis in the current catalog.

For research-reference handling and compliance context, see the COA library for the published batch-evidence pattern that ships with restocked lines, and the reconstitution calculator for the broader peptide-handling tooling on this site.